Guidelines For Paediatric Clinical Practice Of High Quality
Pediatric clinical practice guidelines (CPGs) have lacked a full review in recent years....
Read More
Meeting Coverage
Precision Medicine: It’s All About Biomarker Testing
Guidelines recommend biomarker testing, but is it done? Next-generation sequencing (NGS) may help...
Read More
ESC: Finerenone Demonstrates CVD Benefit in FIGARO-DKD
Benefit driven by 29% relative reduction in heart failure hospitalization SGLT2 inhibitors were...
Read MorePhase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic...
Read More
Race Tied to GI Symptoms During Menopause Transition
THURSDAY, Dec. 16, 2021 (HealthDay News) — Race and ethnicity and menopausal status...
Read MoreCAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL
The first-line, chemotherapy-free regimen of ibrutinib plus venetoclax showed ongoing efficacy after 2 years of follow-up in patients with chronic lymphocytic leukemia (CLL). Patients with confirmed undetected Minimal Residual...
Read More
ASN 2021: A Focus on Chronic Gout eBook
Focus on ASN Chronic Gout.indd
Read MoreReduced risk of Alzheimer’s disease in CHIP carriers
Clonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreUKALL 2003: therapy de-escalation safe in low-risk MRD patients with ALL
Therapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read MoreHeavily pre-treated FLT3-mutated AML population may benefit from novel triplet regimen
A combination treatment of quizartinib plus venetoclax plus decitabine was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia (AML). Patients with RAS/MAPK and FLT3-F691L mutations...
Read MoreEncouraging results of novel triplet combination for AML
A regimen of cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in patients with newly diagnosed acute myeloid leukemia (AML). Moreover, the displayed...
Read MorePromising frontline triplet regimen for TP53-mutated AML
A triplet combination of 5-azacitidine, venetoclax, and magrolimab displayed promising response rates in newly diagnosed older, unfit, or TP53-mutated patients with acute myeloid leukemia (AML). Moreover, the phase 1b/2 study...
Read MoreATLAS-INH: impressive results of fitusiran for hemophilia
Treatment with fitusiran prophylaxis led to a lower rate of bleeding events and an improved health-related quality of life in patients with hemophilia A or B with inhibitors. The observed safety profile of fitusiran in phase 3...
Read MoreJAK2V617F variant allele frequency prognostic of venous events in polycythaemia vera
JAK2V617F variant allele frequency (VAF) >50% is associated with an increased risk of venous thrombosis in patients with polycythaemia vera (PV). This independent predictor distinguished between patients who were classified...
Read MorePersistent disparities in ALL health outcomes
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...
Read More